UCB PRIORITIZES PATIENT VALUE, FOSTERING A CARING CULTURE SHAPED BY INDIVIDUAL NEEDS. EMPHASIZING TECH-DRIVEN INNOVATION AND HUMAN-CENTRIC HEALTHCARE, WE LEVERAGE AI AND DIGITAL STRATEGIES TO ADVANCE PATIENT CARE..
At UCB, we come together every day to work, laser-focused, on a simple question: How will this create value for people living with severe diseases?
Patient value is not just what we say but how we live. It is our culture of care, embodied by our Patient Value Strategy. That’s because how we do business – from discovery to development to delivery – has been transformed and redesigned around people and their individual
experiences. We amplify scientific innovation through digital transformation and commit to making solutions as accessible as possible in ways that are sustainable for people impacted by severe diseases, for UCB, and for society. By keeping people at the heart of everything we do, we push scientific boundaries, seeking to solve the tough challenges to create tangible improvements in care.
Our Patient Value Strategy extends to human-centric healthcare innovation which prioritizes patients’ needs and preferences. Listening and engaging with our patients, from early research to late-stage development, means that we can build partnerships that garner insights into their conditions. Digital technology enables us to enhance our strategy with “data-driven decisions” and improve patient engagement and communication.
Patients today need solutions beyond just medicines to live healthier lives. Through our digital business transformation, we believe a more connected, more patient-centric healthcare ecosystem is possible. With the right partners, the right capabilities and tools, and our passion that powers it all, we can lead the way in transforming the patient experience, paving the way to better health.
Our people, with their diversity, unique strengths, and talents, enable us to fulfill our digital commitment to patients. With a team of approximately 8,600 employees and operations in nearly 40 countries, we invest about a quarter of our revenue annually in cutting-edge scientific research to meet unmet patient needs. With a global headquarters in Brussels, Belgium, UCB maintains its U.S. headquarters in Atlanta, Georgia, with additional U.S. sites in North Carolina, Massachusetts, Washington State, and Washington, D.C.
Established in 1994, UCB’s 47-acre Atlanta campus is home to more than 425 employees who support our U.S. operations, including IT, finance, marketing, communications, medical affairs, and more. We were pleased to announce in 2022 that our Atlanta campus, specifically the new buildout named “The Warehouse,” was awarded the prestigious LEED Gold and WELL Platinum certifications. The Atlanta Warehouse is the first dually certified WELL Platinum and LEED Gold pharmaceutical project in the world and is the first WELL Platinum project in Georgia.
In addition to our green sustainability efforts, UCB is committed to the sustainability of the communities where we live and work. As a science-based company, our community giving targets Science, Technology, Education, and Math (STEM) education with a special focus on K-12 and underserved student populations.
Building on the “Inspiring Science” approach we adopted two years ago, in 2022, UCB contributed to six local STEM education organizations in Atlanta, Boston, and Seattle. Our support of these organizations will foster a stronger workforce for the future of the biopharma industry.
HOW WE DO IT:
EMPOWERING A DIGITAL MINDSET
Our culture empowers a digital-first mindset from the inside out, built on continuous learning and deepening patient understanding. Our digitally-versed teams have the drive, determination, and agile structure to make this transformation happen, always embracing change and never afraid to adapt.
USING DATA AND TECHNOLOGY WITH PURPOSE
The digital capabilities we are building enable us to correlate data to deliver the most actionable insights and uncover unmet needs, allowing our teams to capitalize on urgent opportunities and improve the way we deliver on our patient value ambition.
